About the ACCESS DMD™ program
The intent of an expanded access program is to provide patients with access to investigational medication for serious diseases or conditions where there is no comparable or satisfactory alternative therapy available. The ACCESS DMD™ program will enable participating physicians to obtain and provide deflazacort*, an investigational medication for eligible U.S. patients diagnosed with DMD, while it is under development. The FDA has authorized the use of deflazacort* for eligible patients with DMD under the ACCESS DMD™ expanded access program.
ACCESS DMD™ participants will be provided deflazacort* at no cost while participating in the program, and it will be sent directly to patients or their caregivers.
*Deflazacort is an investigational medication that has not been approved by the Food and Drug Administration (FDA) and is therefore not proven to be safe and effective.